The White House is reviewing a new FDA-biopharma user fee deal that includes
May 29, 2026 01:30 PM EDT
FDA's next fee deal, stacked with US incentives, is under White House review
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
Pharmalittle: We're reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
Landing a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the…
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
With questions already swirling about the actual affordability impact of t | With questions already swirling about the actual…
The FDA's new path, the status of animal testing, and other biotech news from The Readout
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
Commissioner says agency is hiring scientists as industry warns over delays
